

## COMPANY ANNOUNCEMENT

BERLIN | 27.06.2024

### Strategic Acquisition Drives Innovation and Science

The global leader in testing, ALS Limited acquired NUVISAN on April 1, 2024, integrating advanced drug discovery, preclinical and clinical development capabilities into its growing portfolio.

ALS is one of the world's largest and most diversified testing services providers, with sites strategically located around the world to provide accurate and timely services. ALS has operations in more than 350 locations, across 55 countries, and on six continents.

*"With the acquisition by ALS we are excited to further strengthen our global visibility, core drug discovery capabilities and expertise spanning target validation & hit identification to early clinical studies."*



Dr. Charlotte Kopitz, Head of BU Discovery Research & Site Head Berlin

### We are excited about this new journey as part of ALS Group...

With ALS's commitment to high-quality and personalised solutions spanning from drug discovery to post-commercialisation, this strategic acquisition presents specific opportunities for our customers, including:

**Scale and Global Reach:** An expanded service portfolio and geographic reach for clients to access specialised knowledge, cutting-edge technologies, and best-in-class services to tackle complex challenges and explore novel solutions, regardless of your location.

*"The strategic acquisition of NUVISAN by ALS opens exciting new opportunities for innovation and growth. By joining forces, we will be stronger and able to offer a wider range of services, particularly in chemistry. Let's do good science together!"*



Dr. Jean-Guy Boiteau, Head of Chemical Development



**Synergy:** NUVISAN's Contract Research Organization services represent a strategic addition to ALS' existing array of analytical testing capabilities. Maximise value for our clients by providing end-to-end solutions tailored to your specific requirements.

*"In the last three months, we have powerfully embarked on the journey of digitalization that is revolutionizing our daily laboratory work and paving the improvement path to being a high quality related paperless laboratory for the future."*



Dr. Isabel Zwick, Head of Pharmaceutical Analytical

**Continuity of Delivery:** Both organisations have a proven track record of successful delivery, supported by highly experienced management teams, adept at integrating businesses effectively. We have initiated a comprehensive programme to ensure seamless client service and gradual integration.

*“For the past three months, NUVISAN has been fully integrated into ALS, and I am pleased to report that we are maintaining business continuity. This transition creates opportunities to provide new and highly tailored study designs while upholding our dedication to speed and quality.”*



Dr. Piet Swart, Head of BU  
DMPK & Toxicology

For further information, please email us at [hello@nuvisan.com](mailto:hello@nuvisan.com) or visit [www.nuvisan.com](http://www.nuvisan.com) and [www.alsglobal.com](http://www.alsglobal.com)